NZ739493B2 - Pd-1-binding molecules and methods of use thereof - Google Patents
Pd-1-binding molecules and methods of use thereof Download PDFInfo
- Publication number
- NZ739493B2 NZ739493B2 NZ739493A NZ73949316A NZ739493B2 NZ 739493 B2 NZ739493 B2 NZ 739493B2 NZ 739493 A NZ739493 A NZ 739493A NZ 73949316 A NZ73949316 A NZ 73949316A NZ 739493 B2 NZ739493 B2 NZ 739493B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- cancer
- domain
- human
- pdbinding
- seq
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70521—CD28, CD152
-
- G01N33/574—
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
Abstract
The present invention is directed to selected anti-PD-1 antibodies capable of binding to both cynomolgus monkey PD-1 and to human PD-1 : PD-1 mAb 1, PD-1 mAb 2, PD-1 mAb 3, PD-1 mAb 4, PD-1 mAb 5, PD-1 mAb 6, PD-1 mAb 7, PD-1 mAb 8, PD-1 mAb 9, PD-1 mAb 10, PD-1 mAb 11, PD-1 mAb 12, PD-1 mAb 13, PD-1 mAb 14, or PD-1 mAb 15, and to humanized and chimeric versions of such antibodies. The invention additionally pertains to PD-1 -binding molecules that comprise PD-1 binding fragments of such anti-PD-1 antibodies, immunocongugates, and to bispecific molecules, including diabodies, BiTEs, bispecific antibodies, etc., that comprise (i) such PD-1 -binding fragments, and (ii) a domain capable of binding an epitope of a molecule involved in regulating an immune check point present on the surface of an immune cells. The present invention also pertains to methods of using molecules that bind PD-1 for stimulating immune responses, as well as methods of detecting PD-1.
Claims (30)
1. An anti-human PDbinding monospecific monoclonal antibody that comprises a Variable Heavy Chain Domain and a Variable Light Chain Domain, wherein: said Variable Heavy Chain Domain comprises a CDRH1 , a CDRH2 Domain and a CDRH3 Domain, and said Variable Light Chain Domain comprises a CDRL1 Domain, a CDRL2 Domain, and a CDRL3 Domain, wherein: (1) the CDRH1 Domain, CDRH2 Domain, and CDRH3 Domain are the Heavy Chain CDRs of hPD-1 mAb 7(1.2), and respectively comprise the amino acid sequences: SEQ ID NO:139, SEQ ID , and SEQ ID NO:141; and (2) the CDRL1 Domain, CDRL2 Domain, and CDRL3 Domain are the Light Chain CDRs of hPD-1 mAb 7(1.2), and respectively comprise the amino acid sequences: SEQ ID NO:157, SEQ ID NO:145, and SEQ ID NO:146.
2. The anti-human PDbinding monospecific monoclonal dy of claim 1, wherein said antibody comprises a Heavy Chain Variable Domain that comprises the amino acid ce of SEQ ID NO:147 or SEQ ID NO:149.
3. The anti-human PDbinding monospecific monoclonal antibody of any one of claims 1 or 2, wherein said antibody comprises a Light Chain Variable Domain that comprises the amino acid ce of SEQ ID .
4. The anti-human PDbinding monospecific monoclonal dy of any one of claims 1- 3, wherein said antibody comprises a Heavy Chain Variable Domain that comprises the amino acid sequence of SEQ ID NO:147.
5. The anti-human PDantibody of any one of claims 1-3, wherein said antibody comprises a Heavy Chain Variable Domain having the amino acid sequence of SEQ ID NO:147, and wherein said antibody comprises a Light Chain Variable Domain having the amino acid sequence of SEQ ID NO:153.
6. The anti-human PDbinding monospecific monoclonal dy of any one of claims 1- 5, wherein said antibody comprises an Fc Region.
7. The anti-human inding monospecific onal dy of claim 6, n said Fc Region, is of the IgG1, IgG2, IgG3, or IgG4 isotype.
8. The anti-human PDbinding monospecific monoclonal antibody of claim 7, wherein said antibody further comprises a Hinge Domain.
9. The anti-human PDbinding monospecific monoclonal antibody of claim 8, wherein said Fc Region and said Hinge Doman are of the IgG4 isotype, and wherein said Hinge Domain ses a stabilizing mutation.
10. The anti-human PDbinding monospecific monoclonal antibody of any one of claims 6- 8, wherein said antibody comprises SEQ ID NOs: 264 and 265.
11. The anti-human PDbinding monospecific monoclonal antibody of any one of claims 6- 8, wherein said dy comprises SEQ ID NOs: 264 and 266.
12. The anti-human PDbinding monospecific monoclonal antibody of any one of claims 6- 9, wherein said Fc Region is a variant Fc Region that comprises: (a) one or more amino acid modifications that reduces the affinity of the variant Fc Region for an Fc?R; and/or (b) one or more amino acid modifications that enhances the serum half-life of the variant Fc Region.
13. The anti-human PDbinding monospecific monoclonal dy of claim 12, wherein said modifications that reduce the affinity of the variant Fc Region for an Fc?R comprise the substitution of L234A; L235A; or L234A and L235A, n said numbering is that of the EU index as in Kabat.
14. The anti-human PDbinding monospecific monoclonal antibody of claims 12 or 13, wherein said modifications that that enhance the serum ife of the variant Fc Region comprise the substitution of M252Y; M252Y and S254T; M252Y and T256E; M252Y, S254T and T256E; or K288D and H435K, wherein said numbering is that of the EU index as in Kabat.
15. The anti-human PDbinding monospecific monoclonal antibody of any one of claims 1- 14, wherein said antibody is detectably labeled and is used in the ion of PD-1.
16. A composition comprising the anti-human PDbinding monospecific monoclonal antibody of any one of claims 1-14 and a pharmaceutically acceptable r.
17. Use of the anti-human PDbinding monospecific monoclonal antibody of any one of claims 1-14 or the composition of claim 16 for the manufacture of a ment for the treatment of a .
18. The use of claim 17, wherein said cancer is characterized by the presence of a cancer cell selected from the group consisting of a cell of: an adrenal gland tumor, an AIDS-associated cancer, an alveolar soft part sarcoma, an astrocytic tumor, bladder cancer, bone cancer, a brain and spinal cord cancer, a metastatic brain tumor, a breast cancer, a carotid body tumors, a cervical cancer, a chondrosarcoma, a chordoma, a chromophobe renal cell carcinoma, a clear cell carcinoma, a colon cancer, a colorectal cancer, a cutaneous benign fibrous histiocytoma, a desmoplastic small round cell tumor, an ependymoma, a Ewing’s tumor, an extraskeletal myxoid chondrosarcoma, a fibrogenesis imperfecta ossium, a fibrous dysplasia of the bone, a gallbladder or bile duct cancer, gastric cancer, a gestational trophoblastic disease, a germ cell tumor, a head and neck cancer, hepatocellular carcinoma, an islet cell tumor, a Kaposi’s Sarcoma, a kidney cancer, a leukemia, a /benign tous tumor, a liposarcoma/malignant tous tumor, a liver cancer, a lymphoma, a lung cancer, a medulloblastoma, a ma, a meningioma, a multiple endocrine sia, a multiple myeloma, a ysplastic syndrome, a neuroblastoma, a neuroendocrine tumors, an ovarian cancer, a pancreatic cancer, a ary thyroid carcinoma, a parathyroid tumor, a pediatric cancer, a peripheral nerve sheath tumor, a phaeochromocytoma, a pituitary tumor, a prostate cancer, a posterious uveal melanoma, a rare hematologic er, a renal metastatic cancer, a rhabdoid tumor, a rhabdomyosarcoma, a sarcoma, a skin cancer, a soft-tissue sarcoma, a us cell cancer, a stomach cancer, a synovial sarcoma, a testicular cancer, a thymic carcinoma, a thymoma, a thyroid metastatic cancer, and a uterine cancer.
19. The use of claim 17, wherein the cancer is a e .
20. The use of claim 17, wherein the cancer is a squamous cell cancer.
21. The use of claim 17, wherein the cancer is glioma.
22. The use of claim 17, wherein the cancer is a cervical .
23. The use of claim 17, wherein the cancer is kidney cancer.
24. The use of claim 17, wherein the cancer is a lung cancer.
25. The use of claim 17, wherein the cancer is non-small cell lung cancer.
26. The use of claim 17, wherein the cancer is a head and neck cancer.
27. The use of claim 17, wherein the cancer is a renal metastatic cancer.
28. The use of claim 17, wherein the cancer is a chromophobe renal cell carcinoma.
29. The use of claim 17, wherein the cancer is a skin cancer.
30. A nucleic acid expression vector encoding the anti-human PDbinding monospecific monoclonal antibody of any one of claims 1-14. W0 20172’019846 K—coil {or E-coii} Poiypeptide Chain 1 cool-1Wc Linker 12 Linker 2 Poiypeptide Chain 2 COOH WWI: C"1' (or ) Assembled Diabody W0 019846 Polypeptide Chain 1 \
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ778489A NZ778489B2 (en) | 2016-07-28 | PD-1-binding molecules and methods of use thereof | |
| NZ778490A NZ778490A (en) | 2015-07-30 | 2016-07-28 | Pd-1-binding molecules and methods of use thereof |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562198867P | 2015-07-30 | 2015-07-30 | |
| US201562239559P | 2015-10-09 | 2015-10-09 | |
| US201562255140P | 2015-11-13 | 2015-11-13 | |
| US201662322974P | 2016-04-15 | 2016-04-15 | |
| PCT/US2016/044430 WO2017019846A1 (en) | 2015-07-30 | 2016-07-28 | Pd-1-binding molecules and methods use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NZ739493A NZ739493A (en) | 2024-12-20 |
| NZ739493B2 true NZ739493B2 (en) | 2025-03-21 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7166457B2 (en) | Humanized antibody against c-Kit | |
| HRP20211333T1 (en) | Pd-1 and lag-3 binding molecules and methods of use thereof | |
| JP2020501531A5 (en) | ||
| JP7600327B2 (en) | Tetravalent bispecific antibodies targeting PD-1 and VEGF, and methods of producing and using same | |
| JP2018507188A5 (en) | ||
| JP2020510422A5 (en) | ||
| RU2013142600A (en) | PROTEINS CONNECTING SPECIFIC MEMBRANE ANTIGEN AN SIMPLE AND THE RELATED COMPOSITIONS AND METHODS | |
| JP2014530017A5 (en) | ||
| JP2017520575A5 (en) | ||
| RU2018142544A (en) | SPECIFIC BINDING PROTEINS AND WAYS OF THEIR APPLICATION | |
| EP3634998B1 (en) | Anti-cd3 epsilon antibodies | |
| CA2987118A1 (en) | A pdl-1 antibody, pharmaceutical composition thereof and use thereof | |
| JP2016509014A (en) | New multispecific construct | |
| RU2018128414A (en) | NEW PSMA BINDING ANTIBODY AND ITS APPLICATIONS | |
| CA3004804A1 (en) | Pd-l1 antibody, antigen-binding fragment thereof and medical application thereof | |
| JP2017149720A5 (en) | ||
| RU2013125459A (en) | ANTIBODIES AGAINST c-Met RECEPTOR PROTEIN | |
| JP2013545455A5 (en) | ||
| RU2017129236A (en) | MULTIValent MOLECULES CONTAINING DR5-BINDING DOMAINS | |
| JP2020521504A (en) | Anti-CD40 antibody, antigen-binding fragment thereof, and medical use thereof | |
| RU2011151287A (en) | ANTI NOTCH-1 ANTIBODIES | |
| JP2020502233A5 (en) | ||
| CN116940598A (en) | CLDN18.2/CD3 bispecific antibodies for the treatment of solid tumors expressing CLDN18.2 | |
| JP2012530487A5 (en) | ||
| IL272770B2 (en) | CD40 agonist antibodies |